Pfizer's spun-off Zoetis beats estimates on pet-product growth; Can Biogen's new MS pill hit $450M this year?;

@FiercePharma: Pfizer stock down on Q1 shortfall, lowered profits forecast. Sales down 9% to $13.5B. EPS expected at up to $2.24 now, down from $2.30. Results statement | Follow @FiercePharma

@EricPFierce: Novartis to expanded Swiss OTC plant while taking ax to its troubled consumer facility in Lincoln, NE. Article | Follow @EricPFierce

> Pet products boosted Pfizer's ($PFE) spun-off animal health subsidiary Zoetis to a stronger-than-expected quarterly report. Report

> Another week's worth of strong sales numbers for Biogen Idec's ($BIIB) new multiple sclerosis pill Tecfidera fueled hopes for it to outstrip 2013 sales estimates, perhaps hitting as much as $450 million this year. Report

> European Medicines Agency chief Guido Rasi said the agency would appeal an interim court ruling that blocked it from releasing secret clinical trial data on AbbVie ($ABBV) and InterMune ($ITMN) drugs. Report

> The FDA is reviewing caffeine's effects on children and adolescents after Wrigley launched a chewing gum with 40 mg of the drug in each piece. Report

> India's Aurobindo Pharma won final FDA approval to sell four strengths of its generic version of Pfizer's hypertension treatment Accupril. Report

> India and Ghana signed an agreement to work more closely together to develop pharmaceuticals investment and trade. Report

Medical Device News

@FierceMedDev: Experts: Taiwan, Israel should form med device alliance. Item | Follow @FierceMedDev

@MarkHFierce: Today's DxExtra: LipoScience is moving head with development of a cardiovascular Dx that relies on gut flora. More | Follow @MarkHFierce

 @DamianFierce: HeartWare's sales leapt 87% in Q1 thanks to a successful U.S. ventricular pump launch. Article | Follow @DamianFierce

> Asthma devicemaker Aerocrine nabs $50M. More

> German court sides with Boston Scientific rival in stent patent fight. Article

> Qiagen buys Ingenuity Systems for $105M. News

Biotech News

@FierceBiotech: From FierceBiomarkers.com: Brain atrophy could predict multiple sclerosis, study finds. More | Follow @FierceBiotech

@JohnCFierce: Henri Termeer is joining the board at Moderna (big pact with AstraZeneca). Moderna gets my vote for fast co. status. I hope they pull it off. | Follow @JohnCFierce

@RyanMFierce: Sanofi teams with BigData outfit NextBio to research drugs for diabetes and cancer. More | Follow @RyanMFierce

> Biotech upstart joins Big Pharma cast on high-profile 'breakthrough' stage. Item

> Aveo shares plunge after FDA review raises fears of tivozanib rejection. Story

> Regado gambles on $75M IPO to pay pricey PhIII tab. News

Biotech Research News

 @EmilyMFierce: Investigators explore inflammation's role in Parkinson's development. Article | Follow @EmilyMFierce

> Malaria parasite protein could be used to prevent disease transmission. Item

> Gilead drug clears hep B virus in chimpanzees. More

> Zoonotic virus kills human melanoma cells in animal model. Story

> Harvard scientists discover hormone that could treat diabetes. Article

Pharma Manufacturing News

> FDA uncovers foreign-made Botox disguised as U.S. product. News

> Alexion brings in hired guns for troubled plant. Article

> Lonza API plant problems undermine Ipsen's Increlex supplies. More

> Blocking a gene's activity could clear beta-amyloid plaques in Alzheimer's. Story

And Finally... Restaurant menus listing the amount of exercise required to work off each dish forestalled overeating better than those that listed calories, study finds. Report

Suggested Articles

The Pharma Lions shortlist for 2019 lives up to its name with just 31 entries making the cut. But it's still good news for the 12 drugmaker finalists.

Pharma companies filed suit Friday to block the new HHS rule that requires drugmakers to put list prices in TV ads.

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.